Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.68 |
| ▸ | CCNE1 | P24864 | 18/20 | 0.68 |
| ▸ | GSK3B | P49841 | 7/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25335511 | 1.00 | CDK2 (0.68) | CDK2CCNE1GSK3BCCNA2CCNA1 | |
| SCHEMBL30519137 | 0.84 | CDK2 (0.66) | CDK2CCNE1GSK3BCCNA2CCNA1 | |
| SCHEMBL30519064 | 0.84 | CDK2 (0.66) | CDK2CCNE1GSK3BCCNA2CCNA1 | |
| SCHEMBL25334570 | 0.84 | CDK2 (0.66) | CDK2CCNE1GSK3BCCNA2CCNA1 | |
| SCHEMBL30519072 | 0.82 | CCNE1 (0.68) | CDK2CCNE1GSK3B | |
| SCHEMBL25333583 | 0.82 | CCNE1 (0.68) | CDK2CCNE1GSK3B | |
| SCHEMBL31090838 | 0.81 | CDK2 (1.00) | CDK2CCNE1GSK3B | |
| SCHEMBL22312411 | 0.81 | CDK2 (1.00) | CDK2CCNE1GSK3B | |
| SCHEMBL25334611 | 0.81 | CCNE1 (0.66) | CDK2CCNE1GSK3B | |
| SCHEMBL30519002 | 0.81 | CCNE1 (0.66) | CDK2CCNE1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718603-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | CDK2 1/4885CCNE1 8/4885GSK3B 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.